Jump to content

Patented Medicine Prices Review Board

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Tony Tan (talk | contribs) at 22:28, 27 August 2023 (Update Minister of Health to Mark Holland). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Patented Medicine Prices Review Board
Conseil d'examen du prix des médicaments brevetés
Agency overview
Formed1987; 37 years ago (1987)
JurisdictionCanada
HeadquartersOttawa
Employees74
Annual budgetCA$10.3 million[1]
Minister responsible
Agency executives
  • Mitchell Levine, Chairperson
  • Mélanie Bourassa Forcier, Vice-chairperson
  • Douglas Clark, Executive Director
Key document
  • Patent Act
Websitewww.canada.ca/en/patented-medicine-prices-review.html

The Patented Medicine Prices Review Board (French: Conseil d'examen du prix des médicaments brevetés) is a federal quasi-judicial regulatory and reporting agency in Canada with a mandate to protect consumers by ensuring that the prices of patented medication charged by manufacturers of patented drugs are not excessive. The board does this through its role as a regulator, and through its reporting on trends, research and development in the Canadian pharmaceutical industry.[2]

The board investigates, reviews and negotiates the price of individual drugs that are still under patent and which have no generic substitutes. It establishes the maximum prices that can be charged in Canada for patented drugs.[3][4]

Accountability

The board is accountable to Parliament through the Minister of Health, the elected official responsible for the health portfolio. Under sections 89 and 100 of the Patent Act, the board produces an annual report submitted to the minister, who tables it in the House of Commons.[5][6]

Background

Bill C-22, which was passed in 1987, established a compulsory licensing system under which drug patent holders were required to allow competing drug manufacturers to import their patented drug in exchange for a very modest 4% royalty, which resulted in an increase in the market share of generic drugs.[6]: 93  At the same time, it established the federal Patented Medicine Prices Review Board. The board determines a maximum price for individual drugs through a review process, and negotiates "voluntary compliance agreements" with drug companies to ensure that "manufacturer prices are within justification, and [are] not excessive".[6]: 93 

The PMPRB is an independent federal quasi-judicial body established through Section 91 of the Patent Act.[7] Sections 79 through to 103 of the Act set out the mandate, structure, appointment process, and jurisdiction of the Board. The objective of the board is to preventing manufacturers of patented medicines from charging excessive prices.[8]

Annual reports

According to their annual report for the fiscal year 2017, there were 1,391 patented medicines for human use that were reported, which included 80 new medicines. By December 31, 2017, there were 14 voluntary compliance undertakings accepted.[9][10] Patented medicines represented 61.5% of the total medicine sales in Canada in 2017 up from 60.8% in 2016.[9]

Recent PMPRB Reforms

Since 2017, the federal government has been working on passing regulatory changes to how the Patented Medicine Prices Review Board (PMPRB) regulates the excessive pricing of patented medicines in Canada.[8] The Federal Court and Quebec Court of Appeal decisions in Innovative Medicines Canada v. Canada (2022) and Merck Canada inc. v Procureur général du Canada (2022) rebuked the federal government’s initially-proposed changes to the PMPRB as ultra vires the Patent Act.[8] The Trudeau Liberal government has proceeded with subsequent regulatory changes designed to reduce the prices Canadian drug insurers pay for patented medicines.[11] The government has been criticized for their use of the Patent Act and the Patented Medicine Prices Review Board to drive cost savings for drug insurers and for the potential cooling effect this may have in bringing innovative medicines to Canada.[8]

Notes

References

  1. ^ "GC InfoBase". www.tbs-sct.gc.ca. Retrieved 2020-10-16.
  2. ^ "GC InfoBase". www.tbs-sct.gc.ca. Retrieved 2020-10-16.
  3. ^ "Prescription Drug Prices in Canada: What Are the Lessons for the U.S.?". AARP International. Washington, DC.Prescription drug prices in the United States
  4. ^ "Facing crackdown in Canada, drugmakers offered billions in price cuts: Delayed rules would change countries Canada compares its prices to, dropping U.S." Thomson Reuters via CBC. February 6, 2019. Retrieved February 6, 2019.
  5. ^ "ANNUAL REPORT 2018" (PDF).
  6. ^ a b c Menon, Devidas (June 2001). "Pharmaceutical Cost Control in Canada: Does It Work?". Health Affairs. 20: 1–12. doi:10.1377/hlthaff.20.3.92. PMID 11585186. Retrieved February 6, 2019.
  7. ^ Branch, Legislative Services (2021-06-30). "Consolidated federal laws of Canada, Patent Act". laws-lois.justice.gc.ca. Retrieved 2023-03-08.
  8. ^ a b c d Moloney, Kieran (February 2022). "The New Role of the Patented Medicine Prices Review Board (PMPRB)". McGill Journal of Law and Health.
  9. ^ a b "Annual Report 2017". PMPRB. 2018-07-12. Retrieved 2019-02-07.
  10. ^ 1998. Report of the Patented Medicine Prices Review Board. Road Map for the Next Decade Ottawa, Ontario. 36pp.
  11. ^ Government of Canada, Public Works and Government Services Canada (2022-07-06). "Canada Gazette, Part 2, Volume 156, Number 14: Regulations Amending the Regulations Amending the Patented Medicines Regulations (Additional Factors and Information Reporting Requirements), No. 5". canadagazette.gc.ca. Retrieved 2023-03-08.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Patented_Medicine_Prices_Review_Board&oldid=1172566329"